Brand : Temodal 250 mg
Contents :Temozolomide 250 mg
Temodal is a medicine that contains the active substance temozolomide. It is available as capsules.
Temodal is an anticancer medicine. It is used to treat malignant glioma (brain tumours) in the following groups of patients: adults with newly diagnosed glioblastoma multiforme (an aggressive type of brain tumour). Temodal is used first with radiotherapy and then on its own; adults and children three years of age and over with malignant glioma such as glioblastoma multiforme or anaplastic astrocytoma, when the tumour has returned or got worse after standard treatment. Temodal is used on its own in these patients.
The medicine can only be obtained with a prescription.
Treatment with Temodal should be prescribed by a doctor with experience in the treatment of brain tumours.
The dose of Temodal depends on body surface area (calculated using the patient’s height and weight) and ranges from 75 to 200 mg per square metre, once a day. The dose and the number of doses depend on the type of tumour being treated, whether the patient has been treated before, whether Temodal is being used alone or with other treatments, and how the patient responds to treatment. Temodal capsules should be taken without food. If the solution for infusion is used, it should be given over a period of 90 minutes.
Patients may also need to take medicines to prevent vomiting before taking Temodal. Temodal should be used with caution in patients with severe liver problems or with kidney problems.
The active substance in Temodal, temozolomide, belongs to a group of anticancer medicines called alkylating agents. In the body, temozolomide is converted to another compound called MTIC. MTIC binds to the DNA of cells while they are reproducing, which stops cell division. As a result, the cancer cells cannot divide, slowing down the growth of tumours. Temodal should not be used in people who may be hypersensitive (allergic) to temozolomide, any of the other ingredients or dacarbazine (another anticancer medicine). Temodal must not be used in patients with severe myelosuppression (a condition in which the bone marrow cannot make enough blood cells).
Temozolomide belongs to the group of cancer-fighting medications known as antineoplastics, and specifically to the group of antineoplastics known as alkylating agents. Temozolomide prevents the growth of cancer cells by interfering with the genetic material (DNA) that is necessary for reproduction of cells. Because cancer cells reproduce more quickly than normal cells, they are targeted by the medication.
Temozolomide is used to treat specific types of brain tumours.